molecules of the month

first-in-class eIF4A RNA helicase inhibitor

in clinical dev. for solid tumors (Ph. I, IV QW)

from optimization of a natural product

J. Med. Chem., May 29, 2020

eFFECTOR Therapeutics, San Diego, CA